Trade-Ideas LLC identified

LeMaitre Vascular

(

LMAT

) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified LeMaitre Vascular as such a stock due to the following factors:

  • LMAT has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $3.0 million.
  • LMAT has traded 80,479 shares today.
  • LMAT is trading at 2.67 times the normal volume for the stock at this time of day.
  • LMAT is trading at a new high 3.21% above yesterday's close.

'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in LMAT with the Ticky from Trade-Ideas. See the FREE profile for LMAT NOW at Trade-Ideas

More details on LMAT:

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants for the treatment of peripheral vascular disease worldwide. The stock currently has a dividend yield of 1%. LMAT has a PE ratio of 42. Currently there are 6 analysts that rate LeMaitre Vascular a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for LeMaitre Vascular has been 141,600 shares per day over the past 30 days. LeMaitre Vascular has a market cap of $302.4 million and is part of the health care sector and health services industry. The stock has a beta of 0.48 and a short float of 3.9% with 2.85 days to cover. Shares are up 132.3% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates LeMaitre Vascular as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

Highlights from the ratings report include:

  • Powered by its strong earnings growth of 120.00% and other important driving factors, this stock has surged by 124.83% over the past year, outperforming the rise in the S&P 500 Index during the same period. Turning to the future, naturally, any stock can fall in a major bear market. However, in almost any other environment, the stock should continue to move higher despite the fact that it has already enjoyed nice gains in the past year.
  • LEMAITRE VASCULAR INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, LEMAITRE VASCULAR INC increased its bottom line by earning $0.23 versus $0.21 in the prior year. This year, the market expects an improvement in earnings ($0.38 versus $0.23).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 124.0% when compared to the same quarter one year prior, rising from $0.93 million to $2.09 million.
  • LMAT's revenue growth trails the industry average of 30.2%. Since the same quarter one year prior, revenues slightly increased by 8.7%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • LMAT has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 3.96, which clearly demonstrates the ability to cover short-term cash needs.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.